China Approves First Bispecific Antibody for Rabies Passive Immunization
Event summary
- China Medical System Holdings' Silevimig Injection, a bispecific antibody for rabies passive immunization, received NMPA approval on June 22, 2026.
- The product is the world’s first fully human bispecific antibody targeting dual epitopes of the rabies virus.
- CMS secured exclusive commercialization rights in mainland China and licensing rights across Asia-Pacific, Middle East, and North Africa through a collaboration agreement with Chongqing Genrix Biopharmaceutical.
- Silevimig Injection is indicated for adults following rabies virus exposure and demonstrates broad neutralization against different viral strains.
The big picture
This approval marks a significant milestone in rabies treatment, addressing critical gaps in safety, accessibility, and cost associated with existing passive immunization products. The strategic collaboration with Chongqing Genrix Biopharmaceutical positions CMS to capitalize on the substantial market demand for innovative solutions in rabies post-exposure management.
What we're watching
- Market Penetration
- Whether CMS can significantly increase the low penetration rate of passive immunization products in China, currently at around 15% for Category III cases.
- Commercialization Strategy
- How CMS leverages its existing expert network and market resources to ensure a steady rollout of Silevimig Injection across China.
- Regulatory Expansion
- The pace at which Silevimig Injection secures approvals in other regions beyond mainland China, particularly in the Asia-Pacific, Middle East, and North Africa.